CuraVac is an innovative young company founded to take a newly discovered technique for creating therapeutic vaccines against autoimmune diseases from discovery through to being available for the treatment of humans.
Typical autoimmune diseases that should be treatable by CuraVac vaccines include myasthenia gravis, multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosis.
The pioneering vaccine, already in development, is for the treatment of myasthenia gravis
Through this web site, CuraVac aims to bring its activities to the attention of the wider public who want to know about
CuraVac and its team
and to offer an investment
or donation opportunity
to those who wish to support its work.
After a positive evaluation by a team of 27 experts from the 27 European Union member states, the first vaccine in a series, the myasthenia gravis therapeutic vaccine received in fall 2009 the orphan drug status in Europe.
CuraVac is supported by The Myasthenia Gravis Garden State Chapter
Wall street Journal, September 2, 2010 :